Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Major Manufacturers Covered in This Report
• 1.3 Market Segment by Type
  • 1.3.1 Global Gynaecological Cancer Drugs Market Size Growth Rate by Type (2019-2025)
  • 1.3.2 Alkylating Agent
  • 1.3.3 Plant Alkaloid
  • 1.3.4 Anthracyclines
  • 1.3.5 Antitumor Antibiotic
  • 1.3.6 Others
• 1.4 Market Segment by Application
  • 1.4.1 Global Gynaecological Cancer Drugs Market Share by Application (2019-2025)
  • 1.4.2 Hospital Pharmacies
  • 1.4.3 Retail Pharmacies
  • 1.4.4 E-commerce
• 1.5 Study Objectives
• 1.6 Years Considered

2 Global Growth Trends

• 2.1 Global Gynaecological Cancer Drugs Market Size
  • 2.1.1 Global Gynaecological Cancer Drugs Revenue 2014-2025
  • 2.1.2 Global Gynaecological Cancer Drugs Sales 2014-2025
• 2.2 Gynaecological Cancer Drugs Growth Rate by Regions
  • 2.2.1 Global Gynaecological Cancer Drugs Sales by Regions 2014-2019
  • 2.2.2 Global Gynaecological Cancer Drugs Revenue by Regions 2014-2019
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers

3 Market Share by Manufacturers

• 3.1 Gynaecological Cancer Drugs Sales by Manufacturers
  • 3.1.1 Gynaecological Cancer Drugs Sales by Manufacturers 2014-2019
  • 3.1.2 Gynaecological Cancer Drugs Sales Market Share by Manufacturers 2014-2019
• 3.2 Revenue by Manufacturers
  • 3.2.1 Gynaecological Cancer Drugs Revenue by Manufacturers (2014-2019)
  • 3.2.2 Gynaecological Cancer Drugs Revenue Share by Manufacturers (2014-2019)
  • 3.2.3 Global Gynaecological Cancer Drugs Market Concentration Ratio (CR5 and HHI)
• 3.3 Gynaecological Cancer Drugs Price by Manufacturers
• 3.4 Key Manufacturers Gynaecological Cancer Drugs Plants/Factories Distribution and Area Served
• 3.5 Date of Key Manufacturers Enter into Gynaecological Cancer Drugs Market
• 3.6 Key Manufacturers Gynaecological Cancer Drugs Product Offered
• 3.7 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

• 4.1 Sales and Revenue for Each Type
  • 4.1.1 Alkylating Agent Sales and Revenue (2014-2019)
  • 4.1.2 Plant Alkaloid Sales and Revenue (2014-2019)
  • 4.1.3 Anthracyclines Sales and Revenue (2014-2019)
  • 4.1.4 Antitumor Antibiotic Sales and Revenue (2014-2019)
  • 4.1.5 Others Sales and Revenue (2014-2019)
• 4.2 Global Gynaecological Cancer Drugs Sales Market Share by Type
• 4.3 Global Gynaecological Cancer Drugs Revenue Market Share by Type
• 4.4 Gynaecological Cancer Drugs Price by Type

5 Market Size by Application

• 5.1 Overview
• 5.2 Global Gynaecological Cancer Drugs Sales by Application

6 United States

• 6.1 United States Gynaecological Cancer Drugs Breakdown Data by Company
• 6.2 United States Gynaecological Cancer Drugs Breakdown Data by Type
• 6.3 United States Gynaecological Cancer Drugs Breakdown Data by Application

7 European Union

• 7.1 European Union Gynaecological Cancer Drugs Breakdown Data by Company
• 7.2 European Union Gynaecological Cancer Drugs Breakdown Data by Type
• 7.3 European Union Gynaecological Cancer Drugs Breakdown Data by Application

8 China

• 8.1 China Gynaecological Cancer Drugs Breakdown Data by Company
• 8.2 China Gynaecological Cancer Drugs Breakdown Data by Type
• 8.3 China Gynaecological Cancer Drugs Breakdown Data by Application

9 Rest of World

• 9.1 Rest of World Gynaecological Cancer Drugs Breakdown Data by Company
• 9.2 Rest of World Gynaecological Cancer Drugs Breakdown Data by Type
• 9.3 Rest of World Gynaecological Cancer Drugs Breakdown Data by Application
• 9.4 Rest of World Gynaecological Cancer Drugs Breakdown Data by Countries
  • 9.4.1 Rest of World Gynaecological Cancer Drugs Sales by Countries
  • 9.4.2 Rest of World Gynaecological Cancer Drugs Revenue by Countries
  • 9.4.3 Japan
  • 9.4.4 Korea
  • 9.4.5 India
  • 9.4.6 Southeast Asia

10 Company Profiles

• 10.1 Roche Holdings
  • 10.1.1 Roche Holdings Company Details
  • 10.1.2 Company Description and Business Overview
  • 10.1.3 Sales, Revenue and Market Share of Gynaecological Cancer Drugs
  • 10.1.4 Gynaecological Cancer Drugs Product Introduction
  • 10.1.5 Roche Holdings Recent Development
• 10.2 AstraZeneca
  • 10.2.1 AstraZeneca Company Details
  • 10.2.2 Company Description and Business Overview
  • 10.2.3 Sales, Revenue and Market Share of Gynaecological Cancer Drugs
  • 10.2.4 Gynaecological Cancer Drugs Product Introduction
  • 10.2.5 AstraZeneca Recent Development
• 10.3 Sanofi
  • 10.3.1 Sanofi Company Details
  • 10.3.2 Company Description and Business Overview
  • 10.3.3 Sales, Revenue and Market Share of Gynaecological Cancer Drugs
  • 10.3.4 Gynaecological Cancer Drugs Product Introduction
  • 10.3.5 Sanofi Recent Development
• 10.4 Eli Lilly
  • 10.4.1 Eli Lilly Company Details
  • 10.4.2 Company Description and Business Overview
  • 10.4.3 Sales, Revenue and Market Share of Gynaecological Cancer Drugs
  • 10.4.4 Gynaecological Cancer Drugs Product Introduction
  • 10.4.5 Eli Lilly Recent Development
• 10.5 Pfizer
  • 10.5.1 Pfizer Company Details
  • 10.5.2 Company Description and Business Overview
  • 10.5.3 Sales, Revenue and Market Share of Gynaecological Cancer Drugs
  • 10.5.4 Gynaecological Cancer Drugs Product Introduction
  • 10.5.5 Pfizer Recent Development
• 10.6 Takeda Pharmaceuticals
  • 10.6.1 Takeda Pharmaceuticals Company Details
  • 10.6.2 Company Description and Business Overview
  • 10.6.3 Sales, Revenue and Market Share of Gynaecological Cancer Drugs
  • 10.6.4 Gynaecological Cancer Drugs Product Introduction
  • 10.6.5 Takeda Pharmaceuticals Recent Development
• 10.7 Bristol-Myers Squibb
  • 10.7.1 Bristol-Myers Squibb Company Details
  • 10.7.2 Company Description and Business Overview
  • 10.7.3 Sales, Revenue and Market Share of Gynaecological Cancer Drugs
  • 10.7.4 Gynaecological Cancer Drugs Product Introduction
  • 10.7.5 Bristol-Myers Squibb Recent Development
• 10.8 Merck
  • 10.8.1 Merck Company Details
  • 10.8.2 Company Description and Business Overview
  • 10.8.3 Sales, Revenue and Market Share of Gynaecological Cancer Drugs
  • 10.8.4 Gynaecological Cancer Drugs Product Introduction
  • 10.8.5 Merck Recent Development
• 10.9 Dr Reddy’s Laboratories
  • 10.9.1 Dr Reddy’s Laboratories Company Details
  • 10.9.2 Company Description and Business Overview
  • 10.9.3 Sales, Revenue and Market Share of Gynaecological Cancer Drugs
  • 10.9.4 Gynaecological Cancer Drugs Product Introduction
  • 10.9.5 Dr Reddy’s Laboratories Recent Development
• 10.10 Johnson & Johnson
  • 10.10.1 Johnson & Johnson Company Details
  • 10.10.2 Company Description and Business Overview
  • 10.10.3 Sales, Revenue and Market Share of Gynaecological Cancer Drugs
  • 10.10.4 Gynaecological Cancer Drugs Product Introduction
  • 10.10.5 Johnson & Johnson Recent Development
• 10.11 GlaxoSmithKline
• 10.12 Apotex
• 10.13 Hoffmann-La Roche
• 10.14 Novartis
• 10.15 Pfizer
• 10.16 Teva Pharmaceutical

11 Value Chain and Sales Channels Analysis

• 11.1 Value Chain Analysis
• 11.2 Sales Channels Analysis
  • 11.2.1 Gynaecological Cancer Drugs Sales Channels
  • 11.2.2 Gynaecological Cancer Drugs Distributors
• 11.3 Gynaecological Cancer Drugs Customers

12 Market Forecast

• 12.1 Global Gynaecological Cancer Drugs Sales and Revenue Forecast 2019-2025
• 12.2 Global Gynaecological Cancer Drugs Sales Forecast by Type
• 12.3 Global Gynaecological Cancer Drugs Sales Forecast by Application
• 12.4 Gynaecological Cancer Drugs Forecast by Regions
  • 12.4.1 Global Gynaecological Cancer Drugs Sales Forecast by Regions 2019-2025
  • 12.4.2 Global Gynaecological Cancer Drugs Revenue Forecast by Regions 2019-2025
• 12.5 United States Market Forecast
• 12.6 European Union Market Forecast
• 12.7 China Market Forecast
• 12.8 Rest of World
  • 12.8.1 Japan
  • 12.8.2 Korea
  • 12.8.3 India

13 Research Findings and Conclusion

14 Appendix

• 14.1 Research Methodology
  • 14.1.1 Methodology/Research Approach
    • 14.1.1.1 Research Programs/Design
    • 14.1.1.2 Market Size Estimation
    • 14.1.1.3 Market Breakdown and Data Triangulation
  • 14.1.2 Data Source
    • 14.1.2.1 Secondary Sources
    • 14.1.2.2 Primary Sources
• 14.2 Author Details

Gynaecological cancers are being diagnosed among women on a large scale and are also emerging as one of the leading causes of death in various regions.
The surge of innovation in gynaecological cancer treatments is attracting all the major participants in the market for cancer drugs. Scientific advances are leading to the new treatment options in the market. Hence, the gynaecological cancer drugs market is also expected to see a significant growth in the coming years.
Increasing investment by government and the private sector in hospitals and presence of specialist surgeons is also resulting in increased number of patients, thereby leading to the increased use of gynaecological cancer drugs.
Rise in focus of vendors on emerging markets, such as Asia-Pacific and LAMEA, is expected to boost the market growth. Currently, multinational companies are focusing on investing in the GCC region as well as Latin America and Africa to expand their global reach and gain a competitive advantage.
In 2019, the market size of Gynaecological Cancer Drugs is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Gynaecological Cancer Drugs.

This report studies the global market size of Gynaecological Cancer Drugs, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Gynaecological Cancer Drugs sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

In global market, the following companies are covered:
Roche Holdings
AstraZeneca
Sanofi
Eli Lilly
Pfizer
Takeda Pharmaceuticals
Bristol-Myers Squibb
Merck
Dr Reddy’s Laboratories
Johnson & Johnson
GlaxoSmithKline
Apotex
Hoffmann-La Roche
Novartis
Pfizer
Teva Pharmaceutical

Market Segment by Product Type
Alkylating Agent
Plant Alkaloid
Anthracyclines
Antitumor Antibiotic
Others

Market Segment by Application
Hospital Pharmacies
Retail Pharmacies
E-commerce

Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)

The study objectives are:
To analyze and research the Gynaecological Cancer Drugs status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Gynaecological Cancer Drugs manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

In this study, the years considered to estimate the market size of Gynaecological Cancer Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025